関連ニュース

Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the M

Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the

Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior no

Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript

Jazz Pharmaceuticals NASDAQ: JAZZ outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gast

Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcript

Jazz Pharmaceuticals is testing a bull flag breakout following a long-term base advance, with confirmation needed above key swing resistance to validate continuation toward new highs.